The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Outcomes of patients who are BCMA-exposed versus BCMA-naïve in penta-R/R myeloma
Aytaj Mammadzadeh, MD, US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS, discusses a retrospective analysis which evaluated the survival outcomes of patients with penta-relapsed/refractory multiple myeloma (penta-RRMM) receiving BCMA-directed therapy versus BCMA-naïve patients. Results demonstrated a significant survival benefit in those receiving BCMA-directed therapy, and Dr Mammadzadeh also comments on the need for novel treatment strategies for these patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
